Abstract
Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.
Keywords: Cancer cachexia, BPC157, muscle atrophy, cytoprotection, hypercatabolism, hypoanabolism.
Current Pharmaceutical Design
Title:BPC157 as Potential Agent Rescuing from Cancer Cachexia
Volume: 24 Issue: 18
Author(s): Eun A. Kang, Young-Min Han, Jeong Min An, Yong Jin Park, Predrag Sikiric, Deok Hwan Kim, Kwang An Kwon, Yoon Jae Kim, Donghwa Yang, Hann Tchah and Ki Baik Hahm*
Affiliation:
- Digestive Disease Center, CHA University Bundang Medical Center, Seongnam,Korea
Keywords: Cancer cachexia, BPC157, muscle atrophy, cytoprotection, hypercatabolism, hypoanabolism.
Abstract: Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.
Export Options
About this article
Cite this article as:
Kang A. Eun, Han Young-Min, An Min Jeong , Park Jin Yong , Sikiric Predrag , Kim Hwan Deok , Kwon An Kwang , Kim Jae Yoon , Yang Donghwa , Tchah Hann and Hahm Baik Ki *, BPC157 as Potential Agent Rescuing from Cancer Cachexia, Current Pharmaceutical Design 2018; 24 (18) . https://dx.doi.org/10.2174/1381612824666180614082950
DOI https://dx.doi.org/10.2174/1381612824666180614082950 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer
MicroRNA pH-Sensitive Polymer-Based Carriers as a Useful Approach for Oral Delivery of Therapeutic Protein: A Review
Protein & Peptide Letters Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design The Role of Heat Shock Proteins in Cisplatin Resistance
Anti-Cancer Agents in Medicinal Chemistry Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry
Current Topics in Medicinal Chemistry Developments in Targeted Therapy of Advanced Gastrointestinal Stromal Tumors
Recent Patents on Anti-Cancer Drug Discovery Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Polymeric Biomaterial and Lipid Based Nanoparticles for Oral Drug Delivery
Current Medicinal Chemistry Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research The Value of Low-dose Prospective Dual-energy Computed Tomography with Iodine Mapping in the Diagnosis of Gastric Cancer
Current Medical Imaging Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Current Medicinal Chemistry Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples
Recent Patents on Biomarkers Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Plant- and Nutraceutical-based Approach for the Management of Diabetes and its Neurological Complications: A Narrative Review
Current Pharmaceutical Design An Overview of the Chemistry and Pharmacological Potentials of Furanones Skeletons
Current Organic Chemistry Natural Products from Plants as Drug Candidates and Lead Compounds Against Leishmaniasis and Trypanosomiasis
Current Medicinal Chemistry Long-Term Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer/Esophagogastric Junction Cancer: A Systematic Review and Meta-Analysis
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry